Sales Improve For Leading firms, But Dark Clouds on The Horizon

Sales for Japan's leading drugmakers, rose by 6% to JPY2,845.8bn (US$24.5bn) in H106, in what BMI believes is an encouraging performance considering the 6.7% cut in reimbursement prices in April. However, operating profits fell by 4.9% to JPY613.8bn (US$5.28bn), according to the Japan Pharmaceutical Manufacturers Association (JPMA), as increasing expenditure on research ate into revenues. R&D investment jumped 25.7% to JPY474.5bn (US$4.08bn). BMI believes this outlay is essential, as Japanese firms are suffering from weak pipelines, which industry sources fear are not sufficient to offset the potential losses in the future as key products come off

To read the full article, please choose one of the following options: